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Introduction
For more than a decade now, we have known that the 
biological properties of erythropoietin (EPO) are not 
restricted to its erythropoietic effects [1], but also include 
very important tissue-protective effects. The 
erythropoietic effects of EPO are mediated by the 
homodimeric EPO receptor (EPOR), a class 1 cytokine 
receptor, and are clinically exploited in the treatment of 
anemia associated with chronic kidney disease, cancer 
and other chronic illnesses. In 1998, Sakanaka and 
colleagues [2] reported that the degree of apoptosis 
caused by brief periods of cerebral ischemia in gerbils 
was augmented when the effects of endogenous EPO 
were blocked (by using a soluble EPOR). This discovery 
formed the basis for the hypothesis that the local 
production of EPO in response to ischemia limits the 
progression and extent of the injury caused by noxious 
stimuli. There is now good evidence that endogenous or 
exogenous (human recom binant) EPO limits the tissue 
injury caused by ischemia and inflammation in the brain 
or other organs [2-8].
The above preclinical studies stimulated the first 
controlled, phase II clinical study (small case series) 
aimed at evaluating both the safety and efficacy (in terms 
of tissue protection) of EPO in patients with stroke 
(Göttingen EPO Stroke Study) [9]. Evaluation of the 
safety profile of EPO was deemed important, as EPO has 
the potential of raising hematocrit and, hence, increasing 
the likelihood of further transient ischemic attacks. 
During the 30-day follow-up period hematocrit, hemo-
globin, and red blood cell counts all remained normal 
despite a high dose of EPO (100,000  IU over 3  days), 
demonstrating that EPO is well tolerated. Clinical assess-
ment using neurological scoring and magnetic resonance 
imaging showed an improvement in neurological activity 
and infarct size 1  month following stroke in patients 
treated with EPO.
The more recent, larger, German Multicenter EPO 
Stroke Trial, which was designed to reproduce the results 
of the Göttingen EPO Stroke Study, unexpectedly 
documented that a combination of EPO and recombinant 
tissue plasminogen activator (tPA) is not advantageous 
and may even be detrimental [10]. Patients were infused 
with 40,000  IU of EPO over 30  minutes within the first 
6  hours after the onset of symptoms and EPO (at the 
same dose) was re-administered 24 and 48 hours after the 
first dose. During the 90-day follow-up period, patients 
that had received EPO had an increased risk of 
intracerebral hemorrhage, brain edema, thromboembolic 
events and death, highlighting the safety risk associated 
with EPO treatment. Moreover, patients who received 
both EPO and tPA (60% of patients) were significantly 
more likely to die than those receiving EPO only. The 
authors speculated that it may be possible that the 
beneficial effects of EPO (observed in the previous trial) 
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may have been abolished by tPA, resulting in a higher 
mortality.
The potential beneficial and/or adverse effects of EPO 
were also investigated in a large, multicenter phase II 
clinical trial in critically ill patients. In patients with 
trauma-hemorrhage, EPO (40,000  IU per week for 
3 weeks) significantly reduced mortality, but also signifi-
cantly increased the incidence of thrombovascular events 
[11]. This trial clearly indicated, for the first time, that the 
tissue-protective effects of EPO may occur in humans 
and can potentially be exploited to limit tissue injury and 
to improve outcome.
The above clinical trials highlight the need to be 
cautious when planning or conducting trials with EPO as 
increases in hematocrit may lead to excessive thrombosis 
and significant adverse effects [12]. The above data also 
indicate that a strategy that delivers the tissue-protective 
effects of EPO without the known adverse effects may 
offer clinical benefit in patients with trauma hemorrhage 
and potentially many other diseases.
Is there a need for an alternative to erythropoietin?
Leist and colleagues [13] first demonstrated that, by 
modifying the protein backbone of EPO (to produce 
carbamylated EPO (CEPO)), one is able to retain the 
tissue-protective effects of EPO. It was found that the 
concentrations (doses) of CEPO that confer tissue 
protection were higher than those that caused erythro-
poiesis, and that its affinity for the ‘classical’ EPOR was 
dramatically reduced. This inevitably also implies that a 
strategy that leads to increased and sustained activation 
of the EPOR (following multiple administrations of high 
doses of EPO) will result in an increase in pro-thrombotic 
events [14,15]. The Early Intervention with EPO Does 
Not Affect the Outcome of AKI (EARYARF) trial did not, 
however, demonstrate a significant increase in serious 
adverse events associated with EPO treatment when 
compared to placebo (154 versus 115, respectively) [14]. 
This is supported by two similar multicenter trials 
(EPO-2 and EPO-3), which have shown that EPO treat-
ment does not increase the incidence of total serious 
adverse events when compared to placebo (158 versus 
259, respectively) [15]. However, the EPO-3 trial did 
demon strate an increase in circulating red cell mass; this 
combined with EPO-induced platelet aggregability may 
contribute to poor tissue perfusion, which is undesirable 
in conditions associated with ischemia/reperfusion. This 
is supported by pre-clinical data that show that if mice 
that overexpress endogenous EPO are subjected to 
cerebral ischemia, the resulting infarct size is larger [16].
Over the past 30  years several other molecules have 
been actively developed that have tissue-protective pro-
per ties but are devoid of any erythropoietic activity. The 
first of these molecules, desialylated-EPO or asialo-EPO, 
was first discovered whilst assessing the biological 
activity of EPO [17]. This was later expanded in the late 
1980s by enzymatically removing the sialic acid moieties 
terminating the oligosaccharides of EPO and thus 
creating a non-erythropoietic EPO analogue (which still 
has high affinity for the EPOR) with a serum half-life of 
up to 2 minutes compared to the very long (several hours) 
half-life of EPO [18,19]. Since 2003, it has been observed 
that asialo-EPO reduces the tissue injury caused by 
cerebral ischemia, spinal cord compression or sciatic 
nerve crush [20] as well as ischemia-reperfusion injury of 
the kidney [21], gut [22] and heart [23] (Table  1). 
Although asialo-EPO is clearly tissue protective, it is still, 
in principle, able to activate the EPOR and, hence, 
continuous/multiple administrations of asialo-EPO may 
still have an impact on the bone marrow and 
erythropoiesis.
This problem stimulated many to search for EPO 
analogues that are tissue-protective without being eryth-
ro poietic [24-27]. One such modification with potassium 
cyanate involves the transformation of all the lysine 
residues in EPO to homocitrulline, which led to the 
development of CEPO (as described above) in 2004. 
CEPO has been demonstrated to be non-erythropoietic 
in vitro (UT-7 cells) and in vivo in the mouse, and, unlike 
asialo-EPO, is unable to bind to the EPOR [13]. Although, 
CEPO does not bind to the EPOR, it has a pharmaco-
dynamic profile (for example, tissue-protective effects) 
similar to those of EPO or asialo-EPO in a variety of 
organs, including the brain [13], heart [28] and kidney 
[29]. The existence of molecules that confer tissue-
protec tion in the absence of erythropoiesis led to the 
development of the hypothesis that the tissue-protective 
effects of EPO are mediated by a receptor that is different 
from the classical EPOR.
A second erythropoietin receptor that is tissue 
protective
In 2004, Brines and colleagues [30] proposed that the 
tissue protective effects of EPO and its derivatives may be 
mediated, in part, by the beta common receptor (βcR). 
The βcR is primarily a signal transduction subunit, which 
is shared by the α-chain subunits of the interleukin-5, 
interleukin-3 and granulocyte-macrophage colony-
stimu lat ing factor receptors. The α-chains are able to 
bind their ligand with low affinity (1 to 100 nM), but the 
complexes are not able to signal in the absence of the 
βcR. On the other hand, the βcR does not measurably 
bind a ligand by itself, but acts as an affinity converter in 
the presence of an α-chain, allowing ligand binding at 
concentrations in the picomolar range. On the cell 
surface the βcR exists as a pre-formed, intertwined dimer 
[31]. It is not until a ligand binds to its corresponding α-
chain subunit that the βcR becomes covalently attached 
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to the α-chain subunit [32]. We know from βcR knock-
out mice that the βcR is not required for erythropoiesis 
as these mice have normal erythrocyte maturation [30]. It 
has also been previously reported that the EPOR 
functionally associates with the βcR [33,34] to generate 
an EPOR-βcR complex, which gives credibility to the 
hypothesis of a second EPO receptor. Further evidence to 
support this hypothesis comes from Campana and 
colleagues [35], who were able to identify a specific 17 
amino acid sequence of EPO that is tissue protective but 
lacks erythropoietic activity, suggesting that EPO may 
have two distinct receptor binding domains. Evidence 
also suggests that the formation of type I cytokine 
receptors is often by spontaneous self-association of 
subunits already present in the cell membrane, where the 
probability of self-assembly is determined by the abun-
dance of each subunit; for example, the probability of 
EPOR homodimerization increases as the concentration 
of EPOR in the membrane rises [36]. The EPOR-βcR 
complex is thought to be locally up-regulated following 
tissue injury [37,38], although the expression/regulation 
of receptor subunits of the βcR family present within the 
cell membrane is not very well understood and requires 
further extensive study. In vitro reports using a differ-
entiated human neuroblastoma SH-SY5Y cell line that 
expresses the EPOR, but not the βcR, demonstrate that 
the protective effects of EPO against staurosporine-
induced apoptosis are mediated by the EPOR homodimer 
[39]. Conversely, studies to demonstrate the cytopro tec-
tive nature of EPO in cells solely expressing the βcR are 
lacking.
Further structure activity relationship studies have 
identified that, in aqueous solutions, the tertiary 
structure of EPO is relatively well defined because of the 
Table 1. All published studies investigating the efficacy of asialo-ePO in pre-clinical models of disease
      Similar efficacy  
Species Model Dose Route Drug protocol Outcome with EPO Reference
Rat Cerebral ischemia/reperfusion 44 μg/kg IV On reperfusion Neuroprotection Yes [20]
Rat Spinal cord compression 10 μg/kg IV After compression Neuroprotection Yes [20]
Rat Sciatic nerve crush 50 μg/kg IV 24 h or 15 minutes  Neuroprotection Yes [20] 
    pre-treatment, or after  
    nerve crush
Rat Neonatal hypoxia-ischemia 80 μg/kg IP 4 h pre-treatment Neuroprotection Yes [55]
Rat Neonatal hypoxia-ischemia 40 μg/kg IP 24 h and 4 h pre-treatment No protection Yes [55]
Rat Spinal cord compression 10 μg/kg IV 24 h pre-treatment Neuroprotection Yes [56]
Mouse Amyotrophic lateral sclerosis 32 μg/kg IP 3 times per week for 9 weeks Neuroprotection Yes [57]
Rat Kainite-induced cell death of  2.5 pmol/ml NA 72 h pre-treatment Tissue protection Yes [57] 
 primary dissociated anterior  
 horn cultures, in vitro
Mouse Bi-lateral renal ischemia/reperfusion  2.5 μg/kg SC 30 minutes pre-treatment Renoprotection Yes [21]
Rat Contrast-induced nephropathy 80 μg/kg IV 1 h pre-treatment Renoprotection Yes [58]
NA Contrast-induced cell death of  25 ng/ml NA 1 h pre-treatment Tissue protection Yes [58] 
 LLC-PK1 cultures, in vitro
Rat Intestine ischemia/reperfusion 5 μg/kg SC 10 minutes pre-treatment,  Intestinal protection Yes [22] 
    30 minutes into ischemia  
    and on reperfusion
Rat Cerebral ischemia/reperfusion 20 μg/kg/day IV Started on reperfusion for  Neuroprotection Yes [59] 
   infusion 4 days
Mouse Uni-lateral renal ischemia/ 15 μg/kg SC 30 minutes pre-treatment Renoprotection Yes [60] 
 reperfusion with diabetes
Gerbil Bi-lateral common carotid  50 μg/kg IP 3 h pre-treatment, on Neuroprotection Yes [61] 
 artery occlusion    reperfusion and 24 h into  
    reperfusion
Mouse 5/6 nephrectomy with  23 μg/kg SC Twice a week for 4 weeks Cardioprotection Yes [62] 
 subsequent heart failure    after establishment of renal  
    dysfunction
Rat Lumbar disc herniation 13.4 μg/kg SC 1 day pre-treatment and  Reduced pain Yes [63] 
    daily for 2 weeks related behavior
It is evident that derivatives of erythropoietin (EPO) are protective to a similar degree, at similar doses, as EPO. These comparisons can be made, in this instance, since 
all of the studies listed here were conducted with an additional control group with EPO. Asialo-EPO, as well as EPO, is beneficial in several different species and disease 
targets associated with the brain, spinal cord, kidney, heart and intestine via multiple routes of administration. For comparison, EPO at 5,000 IU/kg = 25 μg/kg = 
714 pmol/kg and for asialo-EPO at 23 μg/kg = 714 pmol/kg. EPO, erythropoietin; IP, intraperitoneal; IV, intravenous; NA, not applicable; SC, subcutaneous.
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interaction of the hydrophobic content of its four α-
helices (A, B, C and D helices), constraining the molecule 
into a compact, relatively rigid, globular structure. When 
EPO is bound to the EPOR [40], helix B and parts of the 
AB and CD loops face the aqueous medium, away from 
the binding sites of EPOR (Protein Data Bank (PDB) ID 
code 1EER). These regions do not contain lysine and, 
therefore, are not modified by carbamylation of EPO [41]. 
Further surface-stimulation analysis of EPO found that a 
select set of amino acids on the aqueous face of helix B 
possesses pharmacodynamic activity similar to EPO, 
without having any erythropoietic activity. Based on 
these studies, a peptide called pyroglutamate helix B 
surface peptide (pHBSP) has been generated. pHBSP 
(identical to ARA-290) has been shown to be tissue-
protective in numerous preclinical models of ischemia-
reperfusion injury (kidney, brain, heart) and trauma 
hemorrhage [42-44]. There is very recent evidence that 
the EPOR-βcR complex may be the tissue-protective 
receptor for EPO and its analogues; for instance, pHBSP 
produces a sustained inhibition of hypersensitivity after 
nerve injury in mice, which is abolished in βcR knock-out 
mice [45]. Similarly, EPO treatment reduced the degree 
of spinal cord injury in a model of spinal cord com-
pression and this protection was lost in βcR knock-out 
mice subjected to spinal cord injury [30]. Unfortunately, 
it is not possible to prove in knock-out animals if the 
same is true for EPOR as mice with a targeted deletion 
for EPOR are not viable [46].
erythropoietin derivatives in clinical trials - where 
are they?
To date, there have been numerous clinical trials with 
EPO that have, for the most part, failed to demonstrate 
any clear efficacy, especially in the setting of acute kidney 
injury (AKI) [14] or myocardial infarction [47]. For instance, 
the Reduction of Infarct Expansion and Ventricular 
Remodeling with EPO After Large Myocardial Infarction 
(REVEAL) trial [47] included 222 patients with acute ST-
segment elevation myocardial infarction who underwent 
successful percutaneous coronary intervention. EPO was 
administered at a dose of 60,000 IU within 4 hours of 
reperfusion of the previously ischemic myocardium. 
However, EPO did not reduce infarct size (primary 
endpoint) at any point in the 12-week study period. In 
fact, the study revealed that older patients (>70  years) 
receiving EPO had a 41.2% larger infarct size during the 
first week. In addition, the incidence of both adverse and 
serious adverse events was significantly higher in the 
EPO arm (94 of 125 patients) than the placebo arm (50 of 
97 patients), with five deaths due to myocardial 
infarction, stroke, or stent thrombosis occurring in the 
EPO group (while no deaths occurred in the patients 
treated with placebo).
The Trial to Reduce Cardiovascular Events with Aranesp 
Therapy (TREAT) trial [48] included 4,038 patients with 
diabetes, chronic kidney disease and anemia. EPO was 
administered based on a hemoglobin target of 13.0 g/dl 
(that is, a patient with very low hemoglobin would 
require a higher dose of EPO than a patient with 
hemoglobin closer to 13.0 g/dl). EPO did not reduce the 
risk of a cardiovascular event (31.4% versus 29.7%) or 
renal event (32.4% versus 30.5%) when compared to the 
placebo group, but did increase the risk of stroke (5% 
versus 2.6%).
These data tie in well with the German Multicenter 
EPO Stroke Trial as discussed previously [10], which 
demon strated an increased risk of death with EPO 
treatment in stroke patients. In addition, the Correction 
of Hemoglobin and Outcomes in Renal Insufficiency 
(CHOIR) trial involving 1,432 chronic kidney disease 
patients was suspended when 125 and 97 patients 
developed a cardiovascular primary event following EPO 
treatment when hemoglobin levels were targeted at 
13.5 g/dl and 11.3 g/dl, respectively [49]. This, therefore, 
raises the question of whether the use of EPO analogues 
that are devoid of erythropoietic effects would be of 
benefit to patients suffering from anemia?
In contrast, a pilot study to determine the efficacy of 
EPO to prevent AKI in 71 patients scheduled for elective 
coronary artery bypass grafting has been assessed. A 
moderately low dose of EPO (300 IU/kg intravenously) or 
placebo was randomly administered before surgery. The 
incidence of AKI in the placebo group was 29%, which 
was effectively reduced to 8% in the EPO group with no 
apparent evidence of serious adverse events [50].
It would have been most interesting to see whether or 
not CEPO would have had a beneficial effect in the above 
settings as the risks of serious adverse events may be 
reduced as confirmed by preclinical data demonstrating a 
tissue protective effect with CEPO in models of 
myocardial infarction [28,51,52] and renal disease 
[29,53,54]. As yet there are no published clinical data of 
non-erythropoietic derivatives of EPO, although three 
clinical trials were recently completed with CEPO for the 
treatment of stroke and neurodegeneration (ClinicalTrials.
gov ID: NCT00756249, NCT01016366, NCT00870844).
Conclusion
In the past 25  years, many studies have convincingly 
demonstrated that EPO (at low doses), in addition to its 
erythropoietic effects, reduces tissue injury. The erythro-
poietic effects of EPO are mediated by the classical 
EPOR, while the tissue-protective effects of EPO may be 
mediated by a heterocomplex between EPOR and the 
βcR. Several recent clinical trials with EPO (at high 
doses) have demonstrated significant adverse effects 
(secondary to thrombotic events), which outweigh any 
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beneficial effects observed, but it should be mentioned 
that an increase in survival in trauma-patients treated 
with EPO was observed in one large trial [11] and in 
another study there was a reduced incidence of AKI after 
coronary artery bypass graft surgery [50]. One could 
argue that the reason for non-efficacy in the majority of 
EPO trials has been due to the relatively high doses of 
EPO used, whereas pre-clinical studies have, in the most 
part, used relatively low doses of EPO. The reason for this 
disparity is unclear, as patients with anemia are not often 
treated with exceptionally high doses of EPO. It may well 
be possible that EPO at low concentrations may only 
activate the EPOR-βcR complex, but at high concentra-
tions also activates the EPOR homodimer, thus masking 
any tissue-protective effects that may have been observed 
following βcR activation. In hindsight, it would have 
proved useful to dose a third group of patients in clinical 
trials with an equivalent effective dose seen in pre-clinical 
experiments. The clinical evaluation of non-erythro-
poietic derivatives of EPO (CEPO) is ongoing, but 
currently no data from these trials have been reported.
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